Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Purple Biotech (PPBT) Current Assets (2016 - 2025)

Purple Biotech has reported Current Assets over the past 7 years, most recently at $33.3 million for Q4 2022.

  • Quarterly Current Assets fell 31.39% to $33.3 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $33.3 million through Dec 2022, down 31.39% year-over-year, with the annual reading at $33.3 million for FY2022, 31.39% down from the prior year.
  • Current Assets was $33.3 million for Q4 2022 at Purple Biotech, down from $34.3 million in the prior quarter.
  • Over five years, Current Assets peaked at $65.2 million in Q2 2020 and troughed at $8.3 million in Q4 2019.
  • The 5-year median for Current Assets is $39.7 million (2022), against an average of $36.7 million.
  • Year-over-year, Current Assets surged 614.07% in 2020 and then crashed 31.39% in 2022.
  • A 5-year view of Current Assets shows it stood at $8.5 million in 2018, then dropped by 2.49% to $8.3 million in 2019, then surged by 614.07% to $59.3 million in 2020, then decreased by 18.23% to $48.5 million in 2021, then tumbled by 31.39% to $33.3 million in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Current Assets are $33.3 million (Q4 2022), $34.3 million (Q3 2022), and $37.4 million (Q2 2022).